Providers utilize business intelligence to monitor referral patterns and collaborate with clinicians who order their services. Such analytics tools have also been deployed in the specialty to improve productivity, track patient satisfaction and bolster quality.
Epic Systems, the market leading EHR vendor, sued California-based Epic Staffing in 2024, arguing that the company’s name created confusion in the market. The lawsuit was settled out of court, with the employment firm agreeing to a full rebrand.
Some of today’s most popular products promise better immune, adaptogenic, anti-inflammatory, gut, skin or joint health—or combinations of two or more of the above.
The company called the state’s regulation of pharmacy benefit managers “shortsighted,” as it would force the closure of Accredo, a specialty drug dispensary that supplies drugs it says aren’t available anywhere else in the state.
In a lawsuit, the EHR giant accuses Health Gorilla, et al., of posing as patient care entities to gain access to nearly 300,000 medical records, in violation of HIPAA. Health Gorilla vehemently denies the allegations.
The Wall Street Journal obtained a copy of a report from the Senate Judiciary Committee, which reviewed more than 50,000 documents sent by UnitedHealth related to its Medicare Advantage patients. The outlet published the findings of the inquiry.
Less than two years after closing its patient care clinics and selling its telehealth services, Walmart is re-entering healthcare with a new platform to match patients with virtual providers.
HealthExec zooms in on laws passed in Massachusetts, Oregon and California that are set to change how hedge funds interact with patient care organizations.
Make way for MiniMed! Medtronic's diabetes division has filed the necessary paperwork to go public. The company hopes to be traded on Nasdaq under the symbol MMED.
The Pennsylvania-based drug distributor announced it would be buying OneOncology, a physician-led specialty service group in which it already owned a minority stake. The company said the acquisition will complement its "pharmaceutical-centric strategy."